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Abstract
Background: The balance between Th17 cells and regulatory T (Treg) cells has been shown to play an important
role in the development of rheumatoid arthritis (RA). Recent studies have shown that treatment with abatacept
(ABT) or tocilizumab (TCZ) affects Th17 and Treg cell populations. Although not unanimously accepted, several
reports have shown that Treg cells are decreased by ABT and increased by TCZ, and that Th17 cells are decreased
by TCZ. To further investigate the effects of ABT and TCZ on the skewing of T cell populations, we analyzed the
expression of master regulators genes of helper T cell lineages following ABT/TCZ treatment of RA patients.
Methods: Ten patients treated with ABT and 10 patients treated with TCZ were enrolled. Total RNA was extracted
from peripheral blood cells at baseline, and after 12 and 24 weeks of therapy. The expression levels of T-bet, GATA3,
Foxp3 and Ror-γt were semi-quantified using real-time PCR. The relative expression levels were expressed as the
ratios of two genes (T-bet/GATA3, Foxp3/GATA3, Foxp3/T-bet, Foxp3/Ror-γt, Ror-γt/T-bet, Ror-γt/GATA3), and the
changes in these ratios with treatment were determined.
Results: The Foxp3/Ror-γt ratio was decreased after ABT therapy (0.67 ± 0.16 at 24 weeks, P = 0.0034) but was
increased after TCZ therapy (2.00 ± 1.03 at 24 weeks, P = 0.0013). In addition, the Ror-γt/GATA3 ratio was decreased
after TCZ therapy (0.78 ± 0.37 at 24 weeks, P = 0.0008). Except for these ratios, no significant skewing in the
expression of these factors was detected. No significant relationship between clinical response to the treatment and
change in the ratios of these factors was determined.
Conclusion: Treatment with TCZ or ABT differently affected the balance between Foxp3 and Ror-γt expression in
the peripheral blood of patients with RA.
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Background
Rheumatoid arthritis (RA) is an autoimmune systemic
inflammatory disease that affects joints and other tissues.
The mechanisms of the pathology of RA are not well de-
fined, although studies have shown that proinflammatory
cytokines and various types of immune cells play signifi-
cant roles in its development [1]. Recent therapies with
biological agents have shown very good efficacy against
RA. Tumor necrosis factor (TNF) α blockers inhibit the
action of the major proinflammatory cytokine TNFα,
resulting in the down-regulation of inflammatory cas-
cades. On the other hand, the non-TNF blocking agents
abatacept (ABT) and tocilizumab (TCZ) have different
modes of action and might affect T cell activation and
differentiation. ABT inhibits T cell activation by blocking
the binding of the costimulatory molecule CD28 [2],
whereas TCZ blocks interleukin (IL) -6 signaling that
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attenuates inflammatory cascades, and, in addition it
might also affect T cell differentiation [3].
Various recent studies have shown that the balance
between Th17 cells and regulatory T (Treg) cells plays a
critical role in the development of RA [4]. Th17 cells
secrete IL-17 that activates various cell types that are in-
volved in the pathogenesis of RA and that are enriched
in RA synovia [5, 6]. Treg cells interact with various cell
types and regulate autoimmunity and inflammation; they
are also an important player in the pathogenesis of RA
[7]. Potential defects in Treg-mediated tolerance have
been proposed in RA [8]. Based on these background
findings, the changes in T cell subpopulations in patients
with RA who were treated with ABT or TCZ have been
investigated. Several reports showed that treatment with
TCZ induced a decrease in Th17 cells [9, 10] and an
increase in Treg cells [9, 11, 12], whereas a reduction in
Treg cells has been reported after treatment with ABT
[13, 14]. However these findings were not unanimous
and conflicting results have been reported.
CD4+ helper T cell subsets express lineage-specific
transcription factors, referred to as ‘master regulators’.
Retinoic acid receptor-related orphan receptor-γt (Ror-γt)
and forkhead box P3 (Foxp3) have been defined as the
master regulators of Th17 cells and Treg cells, respectively
[15, 16]. In this study, we investigated whether treatment
with TCZ or ABT altered the relative expression levels of
these master regulators in peripheral blood. We hypothe-
sized that, if any change in helper T cell subpopulations is
induced after biological therapy, the balance of the expres-
sion of master regulator genes may be altered. We focused
in particular on the balance between Foxp3 and Ror-γt
expression, corresponding to Treg cells and Th17 cells, re-
spectively. Our results showed that the balance between
Foxp3 and Ror-γt was differently regulated by TCZ and
ABT in patients with RA.
Methods
Patients
Active RA patients who met the 1987 revised criteria of
the American College of Rheumatology (ACR) for the
classification of RA or the 2010 ACR/European league
Against Rheumatism (EULAR) classification criteria
[17, 18], and who were treated with TCZ or ABT
were enrolled. This study was approved by the Saga
University Hospital ethics committee (#2012-05-07),
and written informed consent was obtained from all
patients. Patients were intravenously treated with TCZ
(8 mg/kg) every 4 weeks or with 500 mg of ABT on day 0,
day 14 and day 28, and, thereafter, every 4 weeks.
Clinical assessments
Clinical characteristics were obtained from medical re-
cords. Disease activity was assessed using the Clinical
Disease Activity Index (CDAI) for patients treated with
TCZ, and the Disease Activity Score for 28 joints
(DAS28CRP) for patients treated with ABT.
Real-time PCR
Blood samples were obtained at 0, 12 and 24 weeks after
TCZ or ABT treatment. Peripheral blood was drawn
into a PAXgeneTM RNA tube (PreAnalytiX GmbH,
Switzerland) and was stored at -20 °C. Total RNA was
extracted using the PAXgene Blood RNA kit (Qiagen)
according to the manufacturer’s protocol, and was
concentrated using the RNeasy MinElute Cleanup Kit
(Qiagen). Total RNA (1 μg) was reverse transcribed
using the Transcriptor First Strand cDNA Synthesis kit
(Roche Diagnostics), and real-time PCR was performed
using the LightCycler 480 with SYBR Green I master
(Roche Diagnostics). The expression levels of the four
master regulator genes, T-box transcription factor
expressed in T cells (T-bet), GATA binding protein 3
(GATA3), Foxp3, and Ror-γt were determined. Primer
sequences were as follows: for T-bet, 5′-CGGGA
GAACTTTGAGTCC AT-3′ and 5′-CTGGGAACAG
GATACTGGTTG-3′; for GATA3, 5′-GGCTCTACTA
CAAGCTTCACAATA-3′ and 5′-CGGGTTAAACGA
GCTGTTCT-3′; for FoxP3, 5′-ATCCTGCCACCTG
GAAGAAC-3′ and 5′-CCATCCTCCTTTCCTTGATC
TTG-3′; for Ror-γt, 5′-CCAAGGCTCAGTCATGAGA-
3′ and 5′-ACCCCTCACAGGTGATAAC-3′. GAPDH
was used as a reference gene (Nihon gene research la-
boratories, Sendai, Japan). Normalized gene expression
was derived from the ratio of the mRNA expression of
the gene of interest to the GAPDH mRNA expression in
each sample.
Because T cell numbers were different in each sample,
the expression ratios of two genes (T-bet/GATA3,
Foxp3/GATA3, Foxp3/T-bet, Foxp3/Ror-γt, Ror-γt/T-
bet, Ror-γt/GATA3) were calculated for each point. The
sequential changes in these ratios before and after treat-
ment were determined (the ratios at baseline were
defined as 1.00).
As controls, RNA samples from five healthy adults
(four women and one man) were prepared, and real-
time PCR was performed together with the samples
from the RA patients.
Statistical analysis
The Friedman test was used to compare the ratios of
mRNA expression before and after therapy with the clin-
ical indexes (CDAI and DAS28CRP). Spearman’s test
was applied for correlations between clinical indexes and
the changes in expression ratios. P < 0.05 was considered
statistically significant. All statistical analyses were
performed using Prism version 6 for Mac software
(GraphPad, San Diego, USA).
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Results
Patients and clinical response
The baseline characteristics of the patients are shown in
Table 1. Ten patients were treated with ABT and an
equal number of patients with TCZ. Parameters such as
age, sex ratio, rheumatoid factor (RF), anti-cyclic citrulli-
nated peptide (CCP) antibody positivity, concomitant
methotrexate (MTX), and previous biologics usage, were
not different between the two groups. Concomitant
glucocorticoid was more frequent in the ABT group than
in the TCZ group. In patients treated with ABT, the
DAS28CRP score was decreased from 3.91 ± 1.00 before
treatment to 2.74 ± 1.10 after 24 weeks of treatment
(Table 1, P = 0.0179). According to the EULAR criteria,
the number of patients with a good response, moderate
response, and no response were three, four, and three,
respectively. Three patients were in remission based on
the DAS28CRP score. In the TCZ group, the CDAI was
decreased from 16.5 ± 7.1 before treatment to 6.5 ± 5.3
after 24 weeks of treatment (Table 1, P = 0.0002). Eight
patients showed a good response by EULAR criteria,
and two patients were in remission based on the CDAI.
The expression ratios of master regulator genes
We semi-quantified the expression of four master regu-
lator genes: T-bet, GATA3, Foxp3, and Ror-γt, in periph-
eral blood using real-time PCR. Because the expression
level of Ror-γt was very low and was undetectable when
assaying a small amount of RNA, we prepared RNA
from whole peripheral blood cells rather than purified T
cells. The expression levels of master regulator genes
before and after biological therapy were shown in Fig. 1.
Foxp3 expression was increased after TCZ treatment
(0.00757 ± 0.00459 before TCZ and 0.01028 ± 0.00454 at
24 weeks, P = 0.0131, Fig. 1b), whereas the expressions
of Ror-γt by TCZ, and Foxp3 and Ror-γt by ABT were
not significantly changed. The expression ratios of two
genes were calculated, and the relative changes after
ABT or TCZ treatment were determined. As shown in
Fig. 2, the Foxp3/Ror-γt ratio was decreased after ABT
therapy (0.83 ± 0.37 at 12 weeks and 0.67 ± 0.16 at
24 weeks, P = 0.0034). This ratio was decreased in eight
of ten patients at 12 weeks, and in all patients at
24 weeks. Other ratios showed no significant changes. In
patients treated with TCZ, in contrast to in patients
treated with ABT, the Foxp3/Ror-γt ratio was increased
after the therapy in all but one case at 24 weeks (Fig. 3,
P = 0.0013). The relative ratio was 1.32 ± 0.67 at 12 weeks
and 2.00 ± 0.97 at 24 weeks. In addition, the Ror-γt/
GATA3 ratio was decreased after TCZ treatment (0.99 ±
0.45 at 12 weeks and 0.78 ± 0.37 at 24 weeks, P = 0.0008,
Fig. 3). No significant skewing was detected in other
ratios following treatment. The raw data are presented
in Additional file 1.
The ratio of Foxp3/Ror-γt expression in peripheral
blood cells from five age- and sex-matched healthy con-
trols was compared to that of the RA patients before
treatment, but no significant difference was observed
(6.70 ± 2.23 vs, 6.59 ± 1.23). In addition, comparisons of
other ratios of master regulator gene expression also
showed no significant differences (Additional file 2:
Figure S1).
The correlation between clinical response to ABT or
TCZ and changes in the ratios of master regulators was
analyzed. In the ABT group, the change in the Foxp3/
Ror-γt ratio was not different between patients who
achieved a good/moderate response and those who
showed no response (0.63 ± 0.16 and 0.76 ± 0.15, respect-
ively), and this ratio showed no correlation to the delta
DAS28CRP score (0 and 24 weeks) (Additional file 2:
Figure S2). Similarly, we found no relationship between
the changes in the Foxp3/Ror-γt or the Ror-γt/GATA3 ra-
tio and the delta CDAI (0 and 24 weeks) in patients
treated with TCZ (Additional file 2: Figure S3). We further
analyzed the correlation between these ratios and some
clinical factors (i.e. sex, previous biologics, autoantibodies,
and age). However no clear correlations were observed.
Table 1 Clinical characteristics at baseline and activity of
rheumatoid arthritis before and after therapy
Patient characteristics Abatacept group Tocilizumab group
Number of patients 10 10
Age; yr, mean ± SD 59.8 ± 15.4 57.0 ± 14.0
Female, n (%) 8 (80) 7 (70)
RF positive, n (%) 9 (90) 9 (90)
Anti-CCP Ab positive, n (%) 9 (90) 9 (90)
CRP, mg/dl 2.7 ± 2.1 2.9 ± 3.0
MTX, n (%) 3 (30) 4 (40)
MTX dose, mg/week 10.7 ± 3.1 7.0 ± 2.6
Glucocorticoid, n (%) 9 (90) 3 (30)
Glucocorticoid dose, mg/day 6.3 ± 5.4 6.5 ± 4.1
Previous Biologics, n (%) 6 (60) 6 (60)
Infliximab, n (%) 1 (10)
Etanercept, n (%) 4 (40) 3 (30)
Adalimumab, n (%) 2 (20) 1 (10)
Abatacept, n (%) 2 (20)
DAS28CRP, mean ± SD
Before 3.91 ± 1.00
After 24 weeks 2.74 ± 1.00
CDAI, mean ± SD
Before 16.5 ± 7.1
After 24 weeks 6.5 ± 5.3
CCP Cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, CRP C-reactive
protein, DAS28 Disease Activity Score for 28 joints, MTX Methotrexate, RF
Rheumatoid factor
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Fig. 1 The expression levels of master regulator genes before and after biological therapy. a. Patients treated with abatacept. b. Patients treated









































Fig. 2 Expression ratios of master regulator genes in rheumatoid arthritis patients treated with abatacept. The ratios at baseline (0w) were
defined as 1.00
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Discussion
Several recent studies have shown that the frequency of
Th17 cells and Treg cells in peripheral blood is altered
by treatment with ABT or TCZ in patients with RA
[9–14, 19–21]. Generally Th17 cells promote auto-
immunity and inflammation, including RA [6, 22],
whereas Treg cells play a role in maintaining immune
responses and preventing autoimmunity [8, 23]. In
addition these two cell types are closely related. Initial
studies reported that these two cell subsets are recipro-
cally regulated and mutually exclusively differentiated
[24]. However, recent studies reported the existence of
Foxp3+ Treg cells that secrete IL-17 [25] and of Ror-γt +
Th17 cells that differentiated from Foxp3+ Treg cells [26].
These data suggest that the development of these two sub-
sets is less stringent than previously thought and that
transition from Treg cells to Th17 cells may occur under
some circumstances.
Unexpectedly we did not found any difference in the
Foxp3/Ror-γt ratio between RA patients at baseline and
healthy controls. Previous studies have shown that Th17
cells were increased and Treg cells were decreased in ac-
tive RA patients (9, 10). However some studies showed
no significant differences in the percentages of Th17
cells (11) or Treg cells (13). It may be helpful to directly
compare the expression levels of master regulators and
the percentages of the T cell subsets and examine
whether both analyses correspond. This still remains to
be addressed.
Regarding ABT treatment of RA patients, it has been
shown that Treg cells are decreased after 3 or 6 months’
treatment [13, 14, 19]. On the other hand, Picchianti
Diamanti A et al. reported that Treg frequency was not
reduced but that function was recovered in patients with
previous TNFα-blocking agent failure [20]. As for Th17
cells, a modest decrease was reported only in anti-CCP
antibody-positive patients [14], or only after 12 months
but not 6 months of treatment [19]. The combined data
indicate that the main effect of ABT on the peripheral
helper T cell population is to reduce Treg cells. Our re-
sult, that the Foxp3/Ror-γt ratio was decreased after
ABT treatment is compatible with the results of those
previous studies. The mechanism of the decrease in the
Treg cell population is not clear; however, our results
suggest that the down-regulation of Foxp3 expression by
ABT leads to a reduction in Treg cells. It is of note that
Foxp3/GATA3 and Foxp3/T-bet ratios showed no sig-
nificant changes with treatment. These data suggested
that ABT has different effects on the expression of Ror-γt,
T-bet and GATA3, and that only Ror-γt expression is up-
regulated. This effect may be due to reciprocal regulation
of Ror-γt and Foxp3 and/or conversion of Foxp3+ Treg
cells to Ror-γt+ Th17 cells [27]. ABT therapy induces a
paradoxical phenomenon, i.e. Treg cells are decreased but
inflammation is alleviated, which is in contrast to the
effect of anti-TNFα and anti-IL-6 therapies [9, 12]. This
phenomenon may be due to the critical role of the CD28-













































Fig. 3 Expression ratios of master regulator genes in rheumatoid arthritis patients treated with tocilizumab. The ratios at baseline (0w) were
defined as 1.00
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functional substitution of Treg cells by ABT, a fusion
protein of cytotoxic T lymphocyte-associated antigen
4 (CTLA4) and immunoglobulin G Fc chain, because
the main machinery by which Treg cell exerts an inhibi-
tory function is CTLA4 [28].
On the other hand, the effects of TCZ on T cell popu-
lations include an increase in Treg cells [9, 11, 12] and a
decrease in Th17 cells [9, 10], although some investiga-
tors have reported that one or both of these populations
were unchanged [11, 12, 21]. In our study, Foxp3 expres-
sion and the Foxp3/Ror-γt expression ratio was in-
creased after TCZ therapy. This result is basically in line
with previous cell population analyses. IL-6, together
with TGF-β, induces the expression of Ror-γt and the
generation of Th17 cells; at the same time, IL-6 inhibits
TGF-β-induced Treg differentiation [29, 30]. It is there-
fore conceivable that a blockade of IL-6 signaling by
TCZ attenuated the expression of Ror-γt and augmented
the expression of Foxp3. Another interesting finding of
our study is that there was a decrease in the Ror-γt/
GATA3 ratio after TCZ therapy. Although a reciprocal
relationship between Th2 cells and Th17 cells has not
been established, TCZ therapy may up-regulate GATA3
expression and the Th2 population. Consistent with
our result, Guggino et al showed an increase in Th2
(CD4+ IFN-γ- IL-17- IL-4+) cells after 3 months of
therapy with TCZ [10].
In our study we did not find any relationship between
clinical response to TCZ or ABT and change in the ex-
pression of master regulators. This finding may be due
to the small sample size, and the small variance in clin-
ical responses especially in patients treated with TCZ,
who all showed a similar response. Alternatively, it is
possible that the clinical response occurs at a time point
after the alteration of master regulator gene expression.
In other words, up-regulation or down-regulation of
genes is induced by treatment with ABT or TCZ, but
differences in subsequent events may modulate their ef-
fect. These subsequent events may include for example:
modification of transcription factors, efficacy of induc-
tion of Th17 cells and Treg cells, or activation of these
cells. Impaired function of Treg cells in RA, and its re-
covery after therapies with ABT or anti-TNF agents has
been reported [13, 20, 30–32]. To address these issues, a
further experiment using a larger population may be
necessary.
Our study has some limitations. First, the expression
of master regulator genes is not limited to CD4 + T cells.
For example, it has been reported that Foxp3 is
expressed in CD8+ T cells or B cells with regulatory
properties and that these cells play a role in RA [33, 34].
Therefore the Foxp3 expression that we measured in our
study may reflect not only Foxp3 expression in CD4+ T
cells but also that in CD8+ T cells and B cells. Second,
Th17 cells and Treg cells do not always strictly develop as
discussed above, and the expression of the master regula-
tor genes may not always correlate with the population
and function of T cells. Treg cells that produce IL-17 have
been identified in patients with RA [35]. Third, because of
the limited numbers of patients, it was unable to compare
the expression ratios in subpopulations. In addition to the
response to the treatment as discussed, sexes, status
of autoantibodies, and previous biologics may make
differences.
Conclusions
Our findings suggest that TCZ and ABT treatment mod-
ulates the expression of Foxp3 and Ror-γt in the periph-
eral blood. It is yet to be determined whether these
changes directly lead to the induction of Treg cells and
Th17 cells, but our data support the previous findings
that the regulations of these cell populations may be one
mode of action of TCZ and ABT.
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